Innoviva EBIT Margin 2010-2023 | INVA
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Innoviva (INVA) over the last 10 years. The current EBIT profit margin for Innoviva as of December 31, 2023 is .
| Innoviva EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$0.31B |
$0.12B |
37.10% |
| 2023-09-30 |
$0.29B |
$0.10B |
34.83% |
| 2023-06-30 |
$0.29B |
$0.37B |
128.28% |
| 2023-03-31 |
$0.32B |
$0.43B |
134.38% |
| 2022-12-31 |
$0.33B |
$0.47B |
143.20% |
| 2022-09-30 |
$0.37B |
$0.56B |
148.79% |
| 2022-06-30 |
$0.40B |
$0.36B |
89.36% |
| 2022-03-31 |
$0.40B |
$0.38B |
94.46% |
| 2021-12-31 |
$0.39B |
$0.38B |
95.67% |
| 2021-09-30 |
$0.38B |
$0.36B |
94.93% |
| 2021-06-30 |
$0.37B |
$0.35B |
94.26% |
| 2021-03-31 |
$0.34B |
$0.32B |
94.19% |
| 2020-12-31 |
$0.34B |
$0.32B |
95.25% |
| 2020-09-30 |
$0.32B |
$0.31B |
95.98% |
| 2020-06-30 |
$0.30B |
$0.29B |
95.67% |
| 2020-03-31 |
$0.29B |
$0.27B |
95.09% |
| 2019-12-31 |
$0.26B |
$0.25B |
94.64% |
| 2019-09-30 |
$0.27B |
$0.25B |
94.34% |
| 2019-06-30 |
$0.26B |
$0.25B |
94.64% |
| 2019-03-31 |
$0.26B |
$0.25B |
94.70% |
| 2018-12-31 |
$0.26B |
$0.24B |
91.57% |
| 2018-09-30 |
$0.25B |
$0.23B |
90.84% |
| 2018-06-30 |
$0.24B |
$0.21B |
88.24% |
| 2018-03-31 |
$0.23B |
$0.20B |
84.78% |
| 2017-12-31 |
$0.22B |
$0.18B |
83.94% |
| 2017-09-30 |
$0.19B |
$0.16B |
80.73% |
| 2017-06-30 |
$0.18B |
$0.14B |
81.25% |
| 2017-03-31 |
$0.15B |
$0.12B |
81.21% |
| 2016-12-31 |
$0.13B |
$0.11B |
82.71% |
| 2016-09-30 |
$0.11B |
$0.09B |
79.46% |
| 2016-06-30 |
$0.09B |
$0.07B |
74.19% |
| 2016-03-31 |
$0.07B |
$0.05B |
66.67% |
| 2015-12-31 |
$0.06B |
$0.03B |
56.36% |
| 2015-09-30 |
$0.04B |
$0.01B |
35.90% |
| 2015-06-30 |
$0.03B |
$-0.00B |
-15.38% |
| 2015-03-31 |
$0.02B |
$-0.02B |
-118.75% |
| 2014-12-31 |
$0.01B |
$-0.04B |
-437.50% |
| 2014-09-30 |
$0.00B |
$-0.02B |
-800.00% |
| 2014-06-30 |
$0.00B |
$-0.01B |
-1400.00% |
| 2014-03-31 |
$0.00B |
$-0.01B |
-1100.00% |
| 2013-12-31 |
$0.00B |
$-0.03B |
-966.67% |
| 2013-09-30 |
$0.01B |
$-0.08B |
-975.00% |
| 2013-06-30 |
$0.01B |
$-0.10B |
-1144.44% |
| 2013-03-31 |
$0.01B |
$-0.13B |
-1466.67% |
| 2012-12-31 |
$0.14B |
$-0.01B |
-9.63% |
| 2012-09-30 |
$0.13B |
$-0.02B |
-14.18% |
| 2012-06-30 |
$0.14B |
$-0.02B |
-10.79% |
| 2012-03-31 |
$0.14B |
$-0.00B |
-2.08% |
| 2011-12-31 |
$0.02B |
$-0.11B |
-478.26% |
| 2011-09-30 |
$0.03B |
$-0.09B |
-368.00% |
| 2011-06-30 |
$0.02B |
$-0.08B |
-345.83% |
| 2011-03-31 |
$0.02B |
$-0.08B |
-325.00% |
| 2010-12-31 |
$0.02B |
$-0.08B |
-325.00% |
| 2010-09-30 |
$0.02B |
$-0.08B |
-385.71% |
| 2010-06-30 |
$0.02B |
$-0.08B |
-372.73% |
| 2010-03-31 |
$0.02B |
$-0.08B |
-400.00% |
| 2009-12-31 |
$0.03B |
$-0.08B |
-324.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.965B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
